Week of May 25, 2026

This week ending May 25, 2026, biotech specialist funds continued to demonstrate concentrated conviction in a handful of mid-cap names, with convergence data revealing meaningful clustering around five core positions. Structure Therapeutics (GPCR) leads the convergence table with 10 distinct funds holding a combined $1.0 billion in the stock, reflecting sustained institutional confidence in the company's oral GLP-1 program as the obesity therapeutics landscape remains fiercely competitive. Close behind, Centessa Pharmaceuticals (CNTA) and Cogent Biosciences (COGT) each attracted nine funds, with aggregate positions of $1.2 billion and $783.1 million respectively, suggesting that specialist allocators are building or defending exposure ahead of anticipated pipeline milestones at both companies. COMPASS Pathways (CMPS) also registered nine-fund convergence at $373.5 million, a signal worth monitoring given the continued institutional debate around psychedelic-assisted therapy commercialization timelines.

The highest-dollar convergence signal this week belongs to Celcuity (CELC), where eight funds have accumulated a combined $2.4 billion in notional exposure — the largest aggregate position among the convergence names and notably outsized relative to the company's market capitalization profile. This level of concentration from specialist investors typically indicates a high-conviction thesis around an upcoming inflection point, and portfolio managers tracking smart-money flows would be well served to scrutinize Celcuity's clinical and regulatory calendar closely in the weeks ahead. When aggregate fund positioning reaches this scale relative to float, liquidity dynamics can shift rapidly on any binary outcome, making position sizing and entry timing particularly consequential for investors considering new exposure.

On the catalyst front, this week and the immediate days following represent an unusually dense binary event window. AstraZeneca (AZN) faces a trifecta of readouts, with Phase 2 data for AZD9550 due today, AZD6234 expected on May 27, and a Phase 3 readout for Durvalumab scheduled for May 29. Amgen (AMGN) is also in focus with Phase 2 results for Anvumetostat, its menin inhibitor program, anticipated on May 27 — a readout that has drawn attention from hematology-focused allocators given the competitive dynamics in the acute myeloid leukemia space. United Therapeutics (UTHR) rounds out the near-term calendar with a Phase 2 readout for rF1V-1018 on May 29, adding a pulmonary medicine data point to what is already a catalyst-heavy close to the month.

For institutional investors, the